Butterfly Network (NYSE: BFLY) is a leader in point-of-care ultrasound, offering the only FDA-cleared, single-probe, whole-body ultrasound system that connects to a smartphone or tablet. The company’s proprietary semiconductor technology and AI-powered tools enable clinicians to perform ultrasound exams at a fraction of the cost and size of traditional systems. Butterfly is targeting a massive addressable market in emergency medicine, primary care, and global health, with a clear path to recurring software revenue.
Investment Thesis
Butterfly Network is at an inflection point. After years of investment in product development and commercial infrastructure, the company is now seeing accelerating revenue growth, expanding gross margins, and a clear path to positive free cash flow. The adoption of its handheld ultrasound is being driven by clinical evidence, AI enhancements, and a shift toward value-based care. With a strong balance sheet and a growing installed base, Butterfly is well-positioned to capture share in the $8B+ global ultrasound market.
12-Month Catalysts
- Revenue Acceleration: Butterfly reported 25% YoY revenue growth in Q1 2026, with software and services revenue growing 40%. The company is on track to achieve its first full year of positive adjusted EBITDA in 2026.
- AI and Software Expansion: The launch of new AI-powered tools (e.g., automated ejection fraction, lung ultrasound) is driving higher attach rates and recurring revenue per device.
- Clinical Adoption and Guidelines: Recent studies showing improved diagnostic accuracy with Butterfly’s device are leading to inclusion in clinical guidelines, boosting hospital procurement.
- International Expansion: Butterfly has secured regulatory approvals in China and India, opening large markets with significant unmet need.
Key Risks
- Competition: Established players like GE, Philips, and Siemens are launching competing handheld devices, and new entrants like Clarius and EchoNous are also targeting the space.
- Reimbursement Uncertainty: While Medicare has expanded coverage for point-of-care ultrasound, private payer reimbursement remains inconsistent, which could slow adoption.
Valuation Summary
Butterfly trades at ~4x forward sales, a discount to high-growth medtech peers. With revenue growth accelerating and margins expanding, the stock could re-rate as the market recognizes its durable competitive advantages. Our price target of $4.50 (50% upside) is based on 5x FY2027 revenue of ~$180M.
Balance Sheet Summary
Butterfly has $120M in cash and no debt, providing ample runway to execute its growth plan. Operating cash burn is narrowing, and the company expects to reach breakeven in Q4 2026.
Disclaimer: This is not financial advice. Investing involves risk, including potential loss of principal. Past performance is not indicative of future results. Always conduct your own due diligence.